Table of Contents
ISRN Cardiology
Volume 2013, Article ID 723435, 7 pages
http://dx.doi.org/10.1155/2013/723435
Review Article

Elevated Cardiac Troponins in Setting of Systemic Inflammatory Response Syndrome, Sepsis, and Septic Shock

Saint Joseph Hospital, Presence Health, Department of Internal Medicine, 2900 North Lake Shore Drive, Chicago, IL 60657, USA

Received 25 February 2013; Accepted 26 March 2013

Academic Editors: L. Liaudet and E. Liehn

Copyright © 2013 Nasir Hussain. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. Guest, A. V. Ramanathan, P. G. Tuteur, K. B. Schechtman, J. H. Ladenson, and A. S. Jaffe, “Myocardoal cell injury in septic shock,” Critical Care Medicine, vol. 27, pp. 1775–1780, 1999. View at Google Scholar
  2. A. Turner, M. Tsamitros, and R. Bellomo, “Myocardial cell injury in septic shock,” Journal of the American Medical Association, vol. 273, pp. 1945–1949, 1999. View at Google Scholar
  3. P. Ammann, T. Fehr, E. Minder, C. Günter, and O. Bertel, “Elevation of troponin I in sepsis and septic shock,” Intensive Care Medicine, vol. 27, no. 6, pp. 965–969, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. D. R. Altmann, W. Korte, M. T. Maeder et al., “Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis,” PLoS ONE, vol. 5, no. 2, Article ID e9017, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Ammann, M. Maggiorini, O. Bertel et al., “Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes,” Journal of the American College of Cardiology, vol. 41, no. 11, pp. 2004–2009, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Favory and R. Neviere, “Bench-to-bedside review: significance and interpretation of elevated troponin in septic patients,” Critical Care, vol. 10, no. 4, article 224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001. View at Google Scholar · View at Scopus
  8. M. Maeder, T. Fehr, H. Rickli, and P. Ammann, “Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides,” Chest, vol. 129, no. 5, pp. 1349–1366, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. J. Fernandes Jr., N. Akamine, and E. Knobel, “Cardiac troponin: a new serum marker of myocardial injury in sepsis,” Intensive Care Medicine, vol. 25, no. 10, pp. 1165–1168, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. K. M. Ver Elst, H. D. Spapen, D. N. Nguyen, C. Garbar, L. P. Huyghens, and F. K. Gorus, “Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock,” Clinical Chemistry, vol. 46, no. 5, pp. 650–657, 2000. View at Google Scholar · View at Scopus
  11. N. J. Mehta, I. A. Khan, V. Gupta, K. Jani, R. M. Gowda, and P. R. Smith, “Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock,” International Journal of Cardiology, vol. 95, no. 1, pp. 13–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Arlati, S. Brenna, L. Prencipe et al., “Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study,” Intensive Care Medicine, vol. 26, no. 1, pp. 31–37, 2000. View at Google Scholar · View at Scopus
  13. C. Spies, V. Haude, R. Fitzner et al., “Serum cardiac troponin T as a prognostic marker in early sepsis,” Chest, vol. 113, no. 4, pp. 1055–1063, 1998. View at Google Scholar · View at Scopus
  14. R. E. Cunnion, G. L. Schaer, and M. M. Parker, “The coronary circulation in human septic shock,” Circulation, vol. 73, no. 4, pp. 637–644, 1986. View at Google Scholar · View at Scopus
  15. J. F. Dhainaut, M. F. Huyghebaert, J. F. Monsallier et al., “Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock,” Circulation, vol. 75, no. 3, pp. 533–541, 1987. View at Google Scholar · View at Scopus
  16. C. W. Lush and P. R. Kvietys, “Microvascular dysfunction in sepsis,” Microcirculation, vol. 7, no. 2, pp. 83–101, 2000. View at Google Scholar · View at Scopus
  17. F. Chagnon, C. N. Metz, R. Bucala, and O. Lesur, “Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization,” Circulation Research, vol. 96, no. 10, pp. 1095–1102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Chagnon, M. Bentourkia, R. Lecomte, M. Lessard, and O. Lesur, “Endotoxin-induced heart dysfunction in rats: assessment of myocardial perfusion and permeability and the role of fluid resuscitation,” Critical Care Medicine, vol. 34, no. 1, pp. 127–133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Levy, D. A. Piel, P. D. Acton et al., “Evidence of myocardial hibernation in the septic heart,” Critical Care Medicine, vol. 33, no. 12, pp. 2752–2756, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Communal, M. Sumandea, P. de Tombe, J. Narula, R. J. Solaro, and R. J. Hajjar, “Functional consequences of caspase activation in cardiac myocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 6252–6256, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Brett, H. Gerlach, P. Nawroth, S. Steinberg, G. Godman, and D. Stern, “Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins,” Journal of Experimental Medicine, vol. 169, no. 6, pp. 1977–1991, 1989. View at Google Scholar · View at Scopus
  22. S. D. Prabhu, “Cytokine-induced modulation of cardiac function,” Circulation Research, vol. 95, no. 12, pp. 1140–1153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. B. Horwich, J. Patel, W. R. MacLellan, and G. C. Fonarow, “Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure,” Circulation, vol. 108, no. 7, pp. 833–838, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Parker, A. F. Suffredini, C. Natanson, F. P. Ognibene, J. H. Shelhamer, and J. E. Parrillo, “Responses of left ventricular function in survivors and nonsurvivors of septic shock,” Journal of Critical Care, vol. 4, no. 1, pp. 19–25, 1989. View at Google Scholar · View at Scopus
  25. J. E. Parrillo, “Myocardial depression during septic shock in humans,” Critical Care Medicine, vol. 18, no. 10, pp. 1183–1184, 1990. View at Google Scholar · View at Scopus
  26. M. M. Parker, J. H. Shelhamer, S. L. Bacharach et al., “Profound but reversible myocardial depression in patients with septic shock,” Annals of Internal Medicine, vol. 100, no. 4, pp. 483–490, 1984. View at Google Scholar · View at Scopus
  27. J. Poelaert, C. Declerck, D. Vogelaers, F. Colardyn, and C. A. Visser, “Left ventricular systolic and diastolic function in septic shock,” Intensive Care Medicine, vol. 23, no. 5, pp. 553–560, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. J. E. Parrillo, M. M. Parker, C. Natanson et al., “Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy,” Annals of Internal Medicine, vol. 113, no. 3, pp. 227–242, 1990. View at Google Scholar · View at Scopus
  29. A. Rudiger and M. Singer, “Mechanisms of sepsis-induced cardiac dysfunction,” Critical Care Medicine, vol. 35, no. 6, pp. 1599–1608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Lim, I. Qushmaq, P. J. Devereaux et al., “Elevated cardiac troponin measurements in critically Ill patients,” Archives of Internal Medicine, vol. 166, no. 22, pp. 2446–2454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Smith, M. John, R. Trout, E. Davis, and S. Moningi, “Elevated cardiac troponins in sepsis: what do they signify?” The West Virginia Medical Journal, vol. 105, no. 4, pp. P29–P32, 2009. View at Google Scholar · View at Scopus
  32. J. L. Vincent, J. Bakker, G. Marecaux, L. Schandene, R. J. Kahn, and E. Dupont, “Administration of anti-TNF antibody improves left ventricular function in septic shock patients; results of a pilot study,” Chest, vol. 101, no. 3, pp. 810–815, 1992. View at Google Scholar · View at Scopus
  33. C. J. Fisher, J. M. Agosti, S. M. Opal et al., “Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein,” The New England Journal of Medicine, vol. 334, no. 26, pp. 1697–1702, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Abraham, M. P. Glauser, T. Butler et al., “p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial,” Journal of the American Medical Association, vol. 277, no. 19, pp. 1531–1538, 1997. View at Google Scholar · View at Scopus
  35. E. Abraham, A. Anzueto, G. Gutierrez et al., “Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock,” The Lancet, vol. 351, no. 9107, pp. 929–933, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. S. M. Opal, C. J. Fisher Jr., J. F. A. Dhainaut et al., “Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial,” Critical Care Medicine, vol. 25, no. 7, pp. 1115–1124, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. Fisher Jr., J. F. A. Dhainaut, S. M. Opal et al., “Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial,” Journal of the American Medical Association, vol. 271, no. 23, pp. 1836–1843, 1994. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Tunçtan, S. Altug, O. Uludag, B. Demirkay, and N. Abacioglu, “Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis,” Pharmacological Research, vol. 48, no. 1, pp. 37–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. R. C. Reddy, G. H. Chen, K. Tateda et al., “Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis,” American Journal of Physiology, vol. 281, no. 3, pp. L537–L543, 2001. View at Google Scholar · View at Scopus
  40. D. Konrad, A. Oldner, P. Rossi, M. Wanecek, A. Rudehill, and E. Weitzberg, “Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock,” Critical Care Medicine, vol. 32, no. 5, pp. 1192–1199, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. T. L. Hwang and C. C. Yeh, “Hemodynamic and hepatic microcirculational changes in endotoxemic rats treated with different NOS inhibitors,” Hepato-Gastroenterology, vol. 50, no. 49, pp. 188–191, 2003. View at Google Scholar · View at Scopus
  42. M. Y. Kirov, O. V. Evgenov, N. V. Evgenov et al., “Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study,” Critical Care Medicine, vol. 29, no. 10, pp. 1860–1867, 2001. View at Google Scholar · View at Scopus
  43. C. D. Raeburn, C. M. Calkins, M. A. Zimmerman et al., “ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation,” American Journal of Physiology, vol. 283, no. 2, pp. R477–R486, 2002. View at Google Scholar · View at Scopus
  44. R. Nevière, B. Guery, S. Mordon et al., “Inhaled NO reduces leukocyte-endothelial cell interactions and myocardial dysfunction in endotoxemic rats,” American Journal of Physiology, vol. 278, no. 6, pp. H1783–H1790, 2000. View at Google Scholar · View at Scopus
  45. T. Suzuki, H. Morisaki, R. Serita et al., “Infusion of the β-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rat,” Critical Care Medicine, vol. 33, no. 10, pp. 2294–2301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. P. Liappis, V. L. Kan, C. G. Rochester, and G. L. Simon, “The effect of statins on mortality in patients with bacteremia,” Clinical Infectious Diseases, vol. 33, no. 8, pp. 1352–1357, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. G. R. Bernard, J. L. Vincent, P. F. Laterre et al., “Efficacy and safety of recombinant human activated protein C for severe sepsis,” The New England Journal of Medicine, vol. 344, no. 10, pp. 699–709, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Annane, “Corticosteroids for septic shock,” Critical Care Medicine, vol. 29, pp. S117–S120, 2001. View at Google Scholar
  49. E. Abraham, P. F. Laterre, R. Garg et al., “Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death,” The New England Journal of Medicine, vol. 353, no. 13, pp. 1332–1341, 2005. View at Publisher · View at Google Scholar · View at Scopus